Reviewing Mateon Therapeutics (MATN) and Ohr Pharmaceuticals (NASDAQ:OHRP)

Mateon Therapeutics (NASDAQ: MATN) and Ohr Pharmaceuticals (NASDAQ:OHRP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Earnings & Valuation

This table compares Mateon Therapeutics and Ohr Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Mateon Therapeutics N/A N/A -$14.36 million ($0.54) -0.66
Ohr Pharmaceuticals N/A N/A -$27.89 million ($0.70) -0.86

Ohr Pharmaceuticals is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mateon Therapeutics and Ohr Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mateon Therapeutics N/A -149.19% -130.72%
Ohr Pharmaceuticals N/A -103.56% -85.09%

Risk & Volatility

Mateon Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Ohr Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Mateon Therapeutics and Ohr Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mateon Therapeutics 0 1 3 0 2.75
Ohr Pharmaceuticals 0 1 1 0 2.50

Mateon Therapeutics currently has a consensus target price of $2.00, indicating a potential upside of 459.13%. Ohr Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 1,560.30%. Given Ohr Pharmaceuticals’ higher probable upside, analysts clearly believe Ohr Pharmaceuticals is more favorable than Mateon Therapeutics.

Institutional & Insider Ownership

8.6% of Mateon Therapeutics shares are owned by institutional investors. Comparatively, 8.3% of Ohr Pharmaceuticals shares are owned by institutional investors. 2.3% of Mateon Therapeutics shares are owned by company insiders. Comparatively, 17.4% of Ohr Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Mateon Therapeutics beats Ohr Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply